WebSection 16 Filings Filing Type: View All 10-Q 10-Q/A 10QSB 10QSB/A NT 10-Q Year: View All 2024 2024 2024 2024 2024 2024 2024 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 WebAug 31, 2024 · SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1933 …
Cytodyn Inc. (CYDY) 10-Q Quarterly Report October 2024
WebJul 2, 2024 · Since 2024, there have been 4 Schedule 13D forms (beneficial ownership report) filed for the company CytoDyn Inc. (stock symbol CYDY) by 3 beneficial owners. A schedule 13D is filed when a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company's equity securities. WebNov 30, 2024 · QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1933 For the transition period from to Commission File Number: … implan slp pdf
CytoDyn Inc. Quarterly Report (Form10) - CytoDyn (OTC:CYDY)
WebDec 7, 2024 · SEC gov • December 07, 2024 ... Download. Exhibits 8-K EX-10.1. Advertisement. Advertisement. Related Filings from CYDY. 10-Q Quarterly report pursuant to Section 13 or 15(d) Jan 09, 2024. 8-K ... WebJan 9, 2024 · Latest Quarterly or Annual Filing. 10-Q. January 9, 2024. Quarterly report pursuant to Section 13 or 15 (d) WebCytoDyn Inc. focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 … implan ortopedi